Diamond Hill Capital Management LLC Investment Advisor Acquires New Shares in uniQure N.V. $QURE

Diamond Hill Capital Management LLC Investment Advisor bought a new position in shares of uniQure N.V. (NASDAQ:QURE) during the second quarter, Holdings Channel reports. The fund bought 17,463 shares of the biotechnology company’s stock, valued at approximately $804,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Avoro Capital Advisors LLC boosted its holdings in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares in the last quarter. State Street Corp boosted its stake in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after buying an additional 1,785,275 shares in the last quarter. Orbimed Advisors LLC grew its stake in shares of uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in uniQure by 23.9% in the 3rd quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock worth $116,073,000 after purchasing an additional 383,066 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on QURE shares. Royal Bank Of Canada increased their price target on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. HC Wainwright lifted their price target on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Leerink Partners boosted their price objective on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Stifel Nicolaus set a $28.00 target price on uniQure in a research note on Tuesday, May 5th. Finally, Chardan Capital increased their price target on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $65.00.

uniQure Stock Down 1.3%

Shares of NASDAQ QURE opened at $47.97 on Tuesday. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The firm has a market capitalization of $3.33 billion, a PE ratio of -11.96 and a beta of 0.93. The firm has a fifty day simple moving average of $41.68 and a two-hundred day simple moving average of $28.04. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The firm had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.45 million. During the same period in the prior year, the business posted ($0.69) EPS. Equities analysts expect that uniQure N.V. will post -3.74 earnings per share for the current year.

Insider Activity

In other uniQure news, insider Walid Abi-Saab sold 30,000 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the transaction, the insider owned 148,235 shares in the company, valued at approximately $6,881,068.70. This represents a 16.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the transaction, the director owned 43,254 shares in the company, valued at approximately $1,949,025.24. This trade represents a 21.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 388,229 shares of company stock valued at $16,817,099. Corporate insiders own 4.65% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.